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Number of New Nonmedical Users of Opioid Analgesics
(Thousands)
Source: SAMHSA (2006). Overview of findings from the 2005 National Survey 
on Drug Use and Health.  (Office of Applied Studies, NSDUH Series H-30, 
DHSS Publication No. SMA 06-4194). Rockville, MD.
Background
Sources of Opioids for Nonmedical Users (% of Respondents)
Plus, of those who got them free,
80% reported that their source got 
the drugs by prescription from a 
single doctor
Internet = percent of people, not amount of drugs
Other = multiple doctors, forged prescription, pharmacy theft.
Source:  Substance Abuse and Mental Health Services Administration. (2010). Results from the 2009
National Survey on Drug Use and Health: Volume I. Summary of National Findings (Office of
Applied Studies, NSDUH Series H-38A, HHS Publication No. SMA 10-4586Findings).  Rockville, MD.
Background
Warner, M., Chen, L. H., & Makuc, D. M. (2009). Increase in fatal poisonings involving 
opioid analgesics in the United States, 1999–2006. NCHS Data Brief, 22.
Are there feasible policy changes that could help to address 



















































Link to Full SFD
Parameter Support
NONMEDICAL USE SECTOR DIRECT INDIRECT PANEL
1 Base Level of Abuse Potential of Pharmaceutical Opioids 1.3
2 Fraction of Demand Met from Chronic Pain Trafficking          .25
3 Fraction of Low Freq Users who switch to High Freq              .06
4 High Frequency User All-Cause Mortality Rate                       .02
5 High Frequency User Cessation Rate                              .08
6 Low Frequency User All-Cause Mortality Rate                       .012
7 Low Frequency User Cessation Rate                               .15
8 Number of Days of Nonmedical Use Among High Freq Users 220
9 Number of Days of Nonmedical Use Among Low Freq Users  30
10 Number of Dosage Units Taken per Day                            2
11 Overdose Mortality Rate for High Freq Nonmedical Users     .002
12 Overdose Mortality Rate for Low Freq Nonmedical Users    .0002
13 Rate of Initiation of Nonmedical Opioid Use                          .006
14 Table Function for the Impact of Limited Accessibility
15 Table Function for the Number of Individuals Using Illicit Drugs
Excluding Marijuana and Pharmaceutical Opioids



























































who Engage in Dr.
Shopping or Forgery
B
Link to Full 
SFD
Parameter Support
DIVERSION SECTOR DIRECT INDIRECT PANEL
1 Average Number of Dosage Units Per Opioid Prescription        86
2 Average Number of Extra Dosage Units Taken/day Among      1.5 
Patients with Abuse or Addiction
3 Fraction of those with Abuse/Addict who Engage in Dr.           .5
Shopping
4 Fraction of those with Abuse/Addict who Engage in Forgery   .4
5 Number of Days of Extra Opioid Usage Among Patients          50 
with Abuse/Addiction
6 Profit Multiplier                                               15
























































Link to full SFD
Parameter Support
MEDICAL USE SECTOR DIRECT INDIRECT PANEL
1 All Cause Mortality Rate for Patients on Long-acting Opioids .012
2 All Cause Mortality Rate for Patients on Short-acting Opioids .01
3 All Cause Mortality Rate for Patients with Abuse/Addiction   .015
4 Average Long-acting Treatment Duration (in years)                  7
5 Average Short-acting Treatment Duration (in years)                  5
6 Base Level of Abuse Potential for Pharmaceutical Opioids 1.3
7 Base Rate for Adding or Switching (to Long-acting)                 .03
8 Base Rate of Opioid Treatment for Pain                                .05-.23                         
9 Base Risk Factor (degree Tx reduced in ‘95 due to risk)           1.3
10 Diagnosis Rate for Chronic Pain                                 .05-.15
11 Overdose Mortality Rate for Patients Abusing Opioids .0015
12 Overdose Mortality Rate for Patients on Long-acting             .0025
13 Overdose Mortality Rate for Patients on Short-acting             .0005 
14 Rate of Addiction for Patients on Long-acting                          .05
15 Rate of Addiction for Patients on Short-acting                          .02
16 Table Function for Short-acting Bias (function of perceived risk)
17 Tamper Resistance (baseline value)                              1
Data Support




































– Simulated as halving the number of patients per year 
who become addicted to opioids
– And doubling prescribers’ perception of risk, which 
halved the fraction of pain patients prescribed opioids
• Popularity Suppression
– Simulated as reducing the rate of initiation by half 











Plots 1, 3, 5
With Prescriber Education:




Implications of Prescriber Education 
Intervention
• Decreased overdose deaths among medical users 
because wary prescribers offer opioid therapy to far 
fewer individuals
– But with possible denial of therapeutic treatment to some 
patients with legitimate chronic pain complaints
• Nonmedical overdose deaths also decrease
– Due to fewer individuals with abuse or addiction who could 
engage in trafficking
– And increased difficulty to obtain fraudulent prescriptions 












Plots 1, 3, 5
With Popularity Suppression:




Implications of Popularity Suppression 
Intervention
• Sharply reduced nonmedical initiation and overall 
population of nonmedical users
• Substantially reduced nonmedical and total overdose 
deaths 
• Once the nonmedical user population declines, 
positive feedback leads to virtuous cycle of decreased 
use and decreased popularity, which further reduces 
use and associated deaths
• Medical usage-related deaths not impacted
• Pain treatment not inhibited
Limitations
• Spotty empirical support
• Focused on trafficking versus interpersonal 
sharing
• Excluded consideration of key issues:
– Effects of poly drug misuse
– Treatment alternatives
– Payor policies (formulary and co-pays)
Future Research
• Use of Monte Carlo analyses to better gauge 
impacts of parameter uncertainty
• Improve model regarding interpersonal 
sharing
• Create models at the individual behavior level
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